Serial No. 10/553,938

## AMENDMENTS TO THE SPECIFICATION

On page 1 of the specification, please amend the first paragraph with the following revised paragraph:

The present Application is a 35 U.S.C. § 371 U.S. national-phase application of International Application No. PCT/US2004/015786, international filing date of 20 May 2004. which claims priority to U.S. Application Serial Number 10/849,615, filed May 20, 2004, now abandoned, and U.S. Provisional Application Serial Number 60/471,958 filed May 20, 2003.

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application 1-33. (canceled)

34. (previously presented) A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain variable region and a heavy chain variable region, wherein:

the light chain variable region comprises:

- a CDRL1 amino acid sequence of SEO ID NO:5:
- a CDRL2 amino acid sequence of SEQ ID NO:13;
- a CDRL3 amino acid sequence SEQ ID NO:19, and

the heavy chain variable region comprises:

- a CDRH1 amino acid sequence of SEQ ID NO:25;
- a CDRH2 amino acid sequence of SEQ ID NO:39; and
- a CDRH3 amino acid sequence of SEQ ID NO:57

35-39. (canceled)

40. (withdrawn) A method of treating B cell lymphoma comprising administering to a subject a composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises-a light chain variable region and a heavy chain variable region, wherein:

the light chain variable region comprises:

04:35:11 p.m. 06-01-2011

- a CDRL1 amino acid sequence of SEQ ID NO:5;
- a CDRL2 amino acid sequence of SEQ ID NO:13; and
- a CDRL3 amino acid sequence of SEQ ID NO:19, and

the heavy chain variable region comprises:

- a CDRH1 amino acid sequence of SEQ ID NO:25;
- a CDRH2 amino acid sequence of SEQ ID NO:39; and
- a CDRH3 amino acid sequence of SEQ ID NO:57.
- 41. (withdrawn) The method of Claim 40, wherein the CD20 binding molecule comprises the AME 33 Fab.
- 42. (withdrawn) The method of Claim 40, wherein the CD20 binding molecule has a binding affinity ( $K_d$ ) for human CD20 of 5.0 x 10<sup>-10</sup> M or less, and a dissociation rate (koff) for human CD20 of 5.0 x 10<sup>-4</sup> s<sup>-1</sup> or less.
- 43. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has a binding affinity ( $K_d$ ) for human CD20 of 1.5 x 10<sup>-10</sup> M or less.
- 44. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has a dissociation rate ( $k_{off}$ ) for human CD20 of 2.5 x  $10^4$  s<sup>-1</sup> or less.
- 45. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has an association rate  $(k_{on})$  for human CD20 of 5.0 x  $10^{-5}$  M<sup>-1</sup> s<sup>-1</sup> or greater.
- 46. (withdrawn) The method of Claim 40, wherein the B cell lymphoma is Non-Hodgkin's lymphoma.
- 47. (withdrawn) The method of Claim 46, wherein the Non-Hodgkin's lymphoma is Waldenstrom's macroglobulinemia.
- 48. (previously presented) The composition of Claim 34, wherein the light chain variable region comprises an amino acid sequence of SEQ ID NO:59 and the heavy chain variable region comprises an amino acid sequence of SEQ ID NO:61.
- 49-50. (canceled)

3172765172 04:35:58 p.m. 06-01-2011 6 /18

Serial No. 10/553,938

51. (previously presented). A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain amino acid sequence of SEQ ID NO:67 and a heavy chain amino acid sequence of SEQ ID NO:69.